All items in the Healthy Skepticism Library
All the 20545 items in the Healthy Skepticism Library are listed below in order of publication date with the most recent at the top. There are 100 items per page.
Page 184 of 206 pages ‹ First < 182 183 184 185 186 > Last ›
HSL4317
 Bleidt B.
 Recent issues and concerns about pharmaceutical industry promotional efforts
 Journal of Drug Issues 1992;22:407-415
 
HSL4319
 Blumenthal D.
 Academic-industry relationships in the life sciences: Extent, consequences, and management.
 JAMA 1992;268:3344-3349
 
HSL4321
 Camerlain M.
 Three cheers for CME
 Canadian Medical Association Journal 1992;146:1153
 
HSL4324
 Caudill TS, Lurie N, Rich EC.
 The influence of pharmaceutical industry advertising on physician prescribing
 Journal of Drug Issues 1992;22:331-338
 
HSL4325
 Cearnal ME.
 Medical marketing communications today: Use and abuse
 Journal of Pharmaceutical Marketing & Management 1992;7:(1):23-32
 
HSL4326
 Chetley A, Mintzes B.
 Promoting health or pushing drugs?
 Health Action International 1992
 
www.haiweb.org
HSL4328
 Chren MM.
 The need for guidelines about pharmaceutical promotions involving gifts to physicians
 Journal of Pharmaceutical Marketing & Management 1992;7:(1):135-145
 
HSL4329
 Cooper RM.
 The Food and Drug Administration's authority to regulate miscellaneous statements by pharmaceutical manufacturers
 Journal of Pharmaceutical Marketing & Management 1992;7:(1):99-120
 
HSL4330
 Cope JD.
 Nonprescription drugs and the regulation of advertising
 Journal of Drug Issues 1992;22:257-264
 
HSL4331
 American Medical Association.Council on Ethical and Judicial Affairs.
 Guidelines on gifts to physicians from industry: an update
 Food Drug Law J. 1992;47:(4):445-58
 
HSL4332
 Cundy T.
 Medical junk mail
 New Zealand Medical Journal 1992;105:437
 
HSL4333
 Data JL, Barton KS.
 Advertising baldly to the public
 New England Journal of Medicine 1992;326:330-331
 
HSL4334
 Davis P.
 The pharmaceutical industry:  a valuable CME resource
 Canadian Journal of CME 1992;4:(8):1-2
 
HSL4335
 Demarco T.
 Should physicians pay for medical journals
 Canadian Family Physician 1992;38:1769
 
HSL4336
 Dickersin K, Min YI, Meinert CL.
 Factors influencing publication of research results: Follow-up of applications submitted to two institutional review boards
 JAMA 1992;267:374-378
 
HSL4337
 Ende M.
 Pharmaceutical promotion
 New England Journal of Medicine 1992;327:1687
 
HSL4338
 Ferner RE, Scott DK.
 The nature and content of advertisements for medicines
 British Journal of Clinical Pharmacology 1992;34:158P
 
HSL4339
 Fink E, Antonelli MA.
 Pharmaceutical ads in Annals
 Annals of Internal Medicine 1992;116:958
 
HSL4341
 Forrest JV.
 Pharmaceutical promotion
 New England Journal of Medicine 1992;327:1687
 
HSL4342
 Freedman M.
 Physicians and pharmaceutical companies
 Canadian Medical Association Journal 1992;146:329
 
HSL4345
 Gans JA.
 The need for guidelines in pharmaceutical promotion: A pharmacy perspective
 Journal of Pharmaceutical Marketing & Management 1992;7:(1):147-155
 
HSL4346
 Girard DE.
 The relationship between physicians in training and pharmaceutical companies:  A time for guidelines?
 Archives of Internal Medicine 1992;152:920-921
 
HSL4348
 Goertzen J.
 Inappropriate layout?
 Canadian Family Physician 1992;38:1769
 
HSL4350
 Gurnee MC, Hansen JM, Sylvestri MF.
 Portrayal of the elderly in drug product advertisements: Relationship to dosing recommendations and pharmacokinetic data in the geriatric population
 Journal of Pharmaceutical Marketing & Management 1992;72:17-31
 
HSL4351
 Hardon A.
 Consumers versus producers:  power play behind the scenes
 1992
 
HSL4355
 Imperato JP.
 Pharmaceutical advertising in the Journal
 New England Journal of Medicine 1992;327:1688
 
HSL4356
 Ingram RA.
 Some comments on direct-to-consumer advertising
 Journal of Pharmaceutical Marketing & Management 1992;7:(1):67-74
 
HSL4359
 Kassirer JP.
 Pharmaceutical advertising in the Journal
 New England Journal of Medicine 1992;327:1689
 
HSL4361
 Kawachi I.
 Where’s the bite?—Six case studies of the voluntary regulation of pharmaceutical advertising and promotion
 1992269-287
 
HSL4362
 Keith A.
 The benefits of pharmaceutical promotion: An economic and health perspective
 Journal of Pharmaceutical Marketing & Management 1992;7:(1):121-133
 
HSL4364
 Kimbel KH.
 Needle money
 Lancet 1992;339:236-237
 
HSL4365
 Krinksy DL.
 Pharmaceutical ads in journals
 Annals of Internal Medicine 1992;117:618
 
HSL4366
 Krupka LR, Vener AM.
 Gender differences in drug (prescription, non-prescription, alcohol and tobacco) advertising:  trends and implications
 Journal of Drug Issues 1992;22:339-360
 
HSL4370
 Lexchin J.
 Pharmaceutical promotion in the Third World
 Journal of Drug Issues 1992;22:417-453
 
HSL4373
 Margolis LH.
 Physicians' interactions with pharmaceutical companies [2nd of two letters]
 Pediatrics 1992;90:281
 
HSL4375
 McGregor A.
 Pharmaceutical industry to be taken to task
 Lancet 1992;339:1103-1104
 
HSL4378
 Medawar C.
 Power and dependence:  Social Audit on the safety of medicines
 : Social Audit 1992
 
http://www.socialaudit.org.uk/122order.htm#1.22%20How%20to%20order
HSL4379
 Menkes DB.
 Medical junk mail
 New Zealand Medical Journal 1992;105:437
 
HSL4380
 Meyer DL.
 Pharmaceutical company-sponsored educational activities: who benefits? who pays?
 Family Medicine 1992;24:565, 568
 
HSL4381
 Montagne M.
 Drug advertising and promotion:  an introduction
 Journal of Drug Issues 1992;22:195-203
 
HSL4382
 Montagne M.
 The promotion of medications for personal and social problems
 Journal of Drug Issues 1992;22:389-405
 
HSL4384
 Morris LA, Griffin JP.
 The evolving role of FDA in prescription drug promotion
 Journal of Drug Issues 1992;22:245-256
 
HSL4385
 Mossinghoff GJ.
 Pharmaceutical manufacturers and self-regulation of drug advertising and promotion
 Journal of Drug Issues 1992;22:235-243
 
HSL4386
 Murphy MN, Smith MC, Juergens JP.
 The synergic impact of promotion intensity and therapeutic novelty on market performance of prescription drug products
 Journal of Drug Issues 1992;22:305-316
 
HSL4387
 Myers MJ.
 Marketing and pharmaceutical development
 Journal of Drug Issues 1992;22:221-234
 
HSL4388
 Narini P.
 Advertising benefits journal readers
 Canadian Family Physician 1992;38:1293
 
HSL4389
 Newton W, Goldstein A, Frey J.
 There is no such thing as a free lunch:  developing policies on pharmaceutical industry support
 Journal of Family Practice 1992;34:32-34
 
HSL4390
 Nixon AJ.
 Physicians and pharmaceutical companies
 Canadian Medical Association Journal 1992;146:(328-329):
 
HSL4402
 Novitch M.
 Beware of offers of indemnity
 New England Journal of Medicine 1992;327:819
 
HSL4403
 O’regan JB.
 Physicians and pharmaceutical companies
 Canadian Medical Association Journal 1992;146:329, 332
 
HSL4404
 Prescription drug advertisements in medical journals
 1992
 
HSL4407
 Paterson AH.
 Physicians and pharmaceutical companies
 Canadian Medical Association Journal 1992;146:328
 
HSL4408
 Payer L.
 Disease-mongers:  how doctors, drug companies, and insurers are making you feel sick
 1992
 
HSL4409
 Peeler CL.
 Pharmaceutical advertising: A Federal Trade Commission perspective
 Journal of Pharmaceutical Marketing & Management 1992;7:(1):157-167
 
HSL4411
 Pines WL.
 Trends in health care consumer communications
 Journal of Pharmaceutical Marketing & Management 1992;7:(1):87-98
 
HSL4413
 Reynolds WJ.
 Trends in advertising pharmaceuticals: A publisher's perspective
 Journal of Pharmaceutical Marketing & Management 1992;7:(1):5-22
 
HSL4414
 Robinson LA.
 Physicians and the pharmaceutical industry
 Canadian Medical Association Journal 1992;147:5822-583
 
HSL4415
 Rogers A.
 EC pharmaceutical directives
 Lancet 1992;339:483
 
HSL4416
 Rosenberg SJ.
 Pharmaceutical promotion
 New England Journal of Medicine 1992;327:1686
 
HSL4418
 Rubenstein DS.
 Pharmaceutical ads in Annals
 Annals of Internal Medicine 1992;116:958
 
HSL4420
 Inappropriate layout?
 Canadian Family Physician 1992;38:1769
 
HSL4421
 Seaver PR.
 Prescription drug advertising: An industry perspective
 Journal of Pharmaceutical Marketing & Management 1992;7:(1):33-41
 
HSL4422
 Sencan N, Üstell I.
 Information in drug advertisements
 199213
 
HSL4424
 Silverman M, Lydecker M, Lee PR.
 Bad medicine:  the prescription drug industry in the Third World
 Stanford University Press 1992
 
HSL4425
 Smith MC.
 Future possibilities in pharmaceutical promotion
 Journal of Drug Issues 1992;22:471-480
 
HSL4427
 Sorofman B.
 Drug promotion in self-care and self-medication
 Journal of Drug Issues 1992;22:377-388
 
HSL4429
 Squires BP.
 Drug information discrepancy
 Canadian Medical Association Journal 1992;147:584, 588
 
HSL4430
 Stallings S.
 From printing press to pharmaceutical representative:  a social history of drug advertising and promotion
 Journal of Drug Issues 1992;22:205-219
 
HSL4431
 Swanson RW.
 Three cheers for CME?
 Canadian Medical Association Journal 1992;146:1519
 
HSL4432
 Taibleson DE.
 Pharmaceutical advertising in the Journal
 New England Journal of Medicine 1992;327:1688
 
HSL4437
 Tarshis GA.
 Pharmaceutical promotion
 New England Journal of Medicine 1992;327:1686
 
HSL4438
 Vandewall J.
 New directions in pharmaceutical advertising
 Journal of Pharmaceutical Marketing and Management 1992;7:(1):75-86
 
HSL4441
 Voth AJ.
 Pharmaceutical ads in Annals
 Annals of Internal Medicine 1992;116:958
 
HSL4442
 Waldholz MR.
 Prescription drug advertising: A critic's perspective
 Journal of Pharmaceutical Marketing & Management 1992;7:(1):43-52
 
HSL4445
 Watts MR, Wilkenfeld JD.
 The role of the Federal Trade Commission in regulating non-prescription drug advertising and promotion
 Journal of Drug Issues 1992;22:265-276
 
HSL4446
 Waud DR.
 Pharmaceutical promotions
 N Engl J Med 1992;327:1688
 
HSL4452
 Wilkes MS, Doblin BH, Shapiro MF.
 Pharmaceutical ads in journals
 Annals of Internal Medicine 1992;117:618-619
 
HSL4453
 Wivell MK, O’fallon DA.
 Drug overpromotion:  when is a warning not a warning?
 Trial 1992;28:(11):20-27
 
HSL4454
 Woollard RF.
 Physicians and pharmaceutical companies
 Canadian Medical Association Journal 1992;146:332
 
HSL4455
 Woolley RJ.
 Pharmaceutical promotion
 New England Journal of Medicine 1992;327:1687
 
HSL4457
 Zerbe RL.
 Beware of offers of indemnity
 New England Journal of Medicine 1992;327:819-820
 
HSL4459
 ASHP policy on the acceptance of advertising.
 Am J Hosp Pharm. 1992 Jan;49:(1):160-1
 
HSL9054
 Kanji N, Hardon A, Mamdani M, Walt G.
 Drugs policy in developing countries
 London: Zed Books 1992.
 
HSL9335
 Chirac P.
 Generics: neither angels nor demons 
 Prescrire International 1992;1:(4):176-179
 
HSL9375
 Koga K, Egawa N, Ohshima T, Mohri T.
 Study of drug advertisements in the journals for physicians and pharmacists 
 Japanese Journal of Hospital Pharmacy 1992;18:(6):661-666
 
HSL9380
 Off-label use of medicines 
 Pharmaceutical Medicine 1992;6:(4):267-271
 
HSL9388
 Alsobrook HB.
 Overview of liability for OTC drugs 
 Drug Information Journal 1992;26:(3):317-328
 
HSL9389
 Bardelay D.
 Pharmaceutical industry needs to pull its socks up! 
 Prescrire International 1992;1:(2):89
 
HSL9423
 Friedman RB, Baum KL, Gable CB.
 Rx to OTC conversions: role of epidemiology 
 Drug Information Journal 1992;26:(2):149-154
 
HSL9425
 Perri M, Wolfgang AP.
 Consumers' cognitive and behavioral responses to health care advertising campaign 
 Journal of Pharmaceutical Marketing Management 1992;6:(3):75-88
 
HSL13309
  Shanteau J.
 The Psychology of Experts: An Alternative View
  Wright G, Bolger F, Eds. Expertise and Decision Support : Springer  1992
 
http://www.amazon.com/Expertise-Decision-Support-Language-Science/dp/0306438623/ref=sr_1_1?ie=UTF8&s=books&qid=1206502465&sr=1-1
HSL19848
 Sigmon JL, Anastasio GD
 Drug Sample Closet
 Journal of Family Practice 1992;34:(3):262-3
 
HSL20231
 Harrigan P
  Australia: rational prescribing in general practice
 The Lancet 1991 Dec 7;338:(1448-1449):
 
http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Medicines-Management/References/1991---January/01/Australia--rational-prescribing-in-general-practice/
HSL4163
 AAFP Congress approves statement on ethics of proprietary relationships.
 Am Fam Physician. 1991 Dec 01;44:(6):2233-9
 
HSL4218
 Rapp MS, Woollard R.
 Two cheers for the CMA's new guidelines on drug company-MD relations The CMA's MD-drug industry guidelines offer advice, nothing more.
 
CMAJ 1991 Dec 1;145:(11):1497-9
 
HSL4232
 Squires BP.
 Medical journals and conflicts of interest.
 
CMAJ 1991 Dec 1;145:(11):1439-40
 
HSL4243
 Woollard R.
 The CMA's MD-drug industry guidelines offer advice, nothing more.
 
CMAJ 1991 Dec 1;145:(11):1498-9
 
HSL4169
 Bayliff CD, Edington RD, Johnston LJ, Shaw PW, Bailey DG.
 Impact of a pharmacist on the educational value of pharmaceutical industry film showings.
 Can J Hosp Pharm 1991 Dec;44:(6):283-7
 
HSL4208
 Margolis LH.
 The ethics of accepting gifts from pharmaceutical companies.
 
Pediatrics 1991 Dec;88:(6):1233-7
 
HSL4221
 Richards JW Jr.
 AAFP white paper on proprietary relationships: just do the right thing.
 
Am Fam Physician 1991 Dec;44:(6):2023
 
Page 184 of 206 pages ‹ First < 182 183 184 185 186 > Last ›
 








 


